JP2018529331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529331A5 JP2018529331A5 JP2018511416A JP2018511416A JP2018529331A5 JP 2018529331 A5 JP2018529331 A5 JP 2018529331A5 JP 2018511416 A JP2018511416 A JP 2018511416A JP 2018511416 A JP2018511416 A JP 2018511416A JP 2018529331 A5 JP2018529331 A5 JP 2018529331A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- amino acid
- mutation
- seq
- acid residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562213466P | 2015-09-02 | 2015-09-02 | |
| US62/213,466 | 2015-09-02 | ||
| PCT/EP2016/070654 WO2017037196A1 (en) | 2015-09-02 | 2016-09-01 | Stabilized viral class i fusion proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020188363A Division JP2021045138A (ja) | 2015-09-02 | 2020-11-12 | 安定化したウイルスクラスｉ融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529331A JP2018529331A (ja) | 2018-10-11 |
| JP2018529331A5 true JP2018529331A5 (enExample) | 2019-08-08 |
| JP6975709B2 JP6975709B2 (ja) | 2021-12-01 |
Family
ID=56855456
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511416A Active JP6975709B2 (ja) | 2015-09-02 | 2016-09-01 | 安定化したウイルスクラスｉ融合タンパク質 |
| JP2020188363A Pending JP2021045138A (ja) | 2015-09-02 | 2020-11-12 | 安定化したウイルスクラスｉ融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020188363A Pending JP2021045138A (ja) | 2015-09-02 | 2020-11-12 | 安定化したウイルスクラスｉ融合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10538557B2 (enExample) |
| EP (2) | EP3344288A1 (enExample) |
| JP (2) | JP6975709B2 (enExample) |
| CN (1) | CN108025057B (enExample) |
| AU (2) | AU2016316723B2 (enExample) |
| CA (1) | CA2997181A1 (enExample) |
| WO (1) | WO2017037196A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018002728A (es) | 2015-09-03 | 2018-09-05 | Novavax Inc | Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas. |
| WO2018081318A1 (en) | 2016-10-25 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
| CN111148509A (zh) | 2017-07-24 | 2020-05-12 | 诺瓦瓦克斯股份有限公司 | 治疗呼吸系统疾病的方法和组合物 |
| IL277274B2 (en) | 2018-03-19 | 2024-02-01 | Novavax Inc | Multifunctional nanoparticle vaccines for influenza |
| BR112021001460A2 (pt) | 2018-08-13 | 2021-04-27 | Janssen Vaccines & Prevention B.V. | trímeros de glicoproteína de filovírus estabilizados |
| CN109142723B (zh) * | 2018-08-21 | 2021-07-13 | 苏州华益美生物科技有限公司 | 人类免疫缺陷病毒快速检测测试卡及其应用 |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| EP4149538A1 (en) | 2020-05-11 | 2023-03-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| PH12022552935A1 (en) | 2020-05-11 | 2024-02-12 | Janssen Pharmaceuticals Inc | Stabilized coronavirus spike protein fusion proteins |
| MX2022014167A (es) | 2020-05-11 | 2023-02-14 | Janssen Pharmaceuticals Inc | Replicón de arn que codifica una proteína de espícula del coronavirus estabilizada. |
| EP4157345A4 (en) * | 2020-05-29 | 2024-09-11 | Board of Regents, The University of Texas System | GENETICALLY MODIFIED CORONAVIRUS SPIKE(S) PROTEIN AND METHODS OF USE THEREOF |
| CN111704657B (zh) * | 2020-06-16 | 2021-11-09 | 四川安可瑞新材料技术有限公司 | Hiv-2重组抗原及其制备方法、用途 |
| BR112022026974A2 (pt) | 2020-07-06 | 2023-01-24 | Janssen Pharmaceuticals Inc | Proteínas de fusão estabilizadas de proteínas de pico de coronavírus |
| US20230270838A1 (en) * | 2020-08-02 | 2023-08-31 | Richard Ascione | Vaccine compositions for influenza viruses and methods of use |
| US20240307486A1 (en) * | 2021-03-30 | 2024-09-19 | Baylor College Of Medicine | Methods and compositions for high-potency polypeptide-based protein inhibition |
| WO2023047349A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| WO2023047348A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
| WO2024061759A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized coronavirus s proteins |
| CN116947982B (zh) * | 2023-07-12 | 2024-05-14 | 吉林大学 | 三条优势表位肽序列及其在流感病毒疫苗的应用 |
| TW202527960A (zh) * | 2023-09-06 | 2025-07-16 | 美商賽諾菲巴斯德公司 | 經修飾ｂ型流感血球凝集素多肽及核酸及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| ES2713864T3 (es) * | 2008-06-05 | 2019-05-24 | Ablynx Nv | Secuencias de aminoácidos dirigidas contra proteínas de la envuelta de un virus y polipéptidos que comprenden las mismas para el tratamiento de enfermedades virales |
| ES2651143T3 (es) * | 2011-05-13 | 2018-01-24 | Glaxosmithkline Biologicals Sa | Antígenos de F de prefusión del VRS |
| JP2014530010A (ja) * | 2011-09-30 | 2014-11-17 | ノババックス，インコーポレイテッド | 呼吸器合胞体ウイルス用の組み換えナノ粒子ｒｓｖｆワクチン |
| MY170927A (en) * | 2011-11-28 | 2019-09-19 | Janssen Vaccines & Prevention Bv | Influenza virus vaccines and uses thereof |
| CN110590916A (zh) * | 2013-04-25 | 2019-12-20 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| US10058604B2 (en) * | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3072901A1 (en) * | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
-
2016
- 2016-09-01 AU AU2016316723A patent/AU2016316723B2/en active Active
- 2016-09-01 JP JP2018511416A patent/JP6975709B2/ja active Active
- 2016-09-01 EP EP16760463.6A patent/EP3344288A1/en not_active Withdrawn
- 2016-09-01 EP EP21200796.7A patent/EP4019044A3/en not_active Withdrawn
- 2016-09-01 CA CA2997181A patent/CA2997181A1/en active Pending
- 2016-09-01 WO PCT/EP2016/070654 patent/WO2017037196A1/en not_active Ceased
- 2016-09-01 US US15/756,800 patent/US10538557B2/en active Active
- 2016-09-01 CN CN201680051120.1A patent/CN108025057B/zh active Active
-
2019
- 2019-12-03 US US16/701,429 patent/US10711042B2/en active Active
-
2020
- 2020-11-12 JP JP2020188363A patent/JP2021045138A/ja active Pending
-
2021
- 2021-03-02 AU AU2021201330A patent/AU2021201330A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529331A5 (enExample) | ||
| JP2013526849A5 (enExample) | ||
| JP2016199557A5 (enExample) | ||
| JP2019521674A5 (enExample) | ||
| JP2009268467A5 (enExample) | ||
| JP2021505201A5 (enExample) | ||
| JP2012521786A5 (enExample) | ||
| JP2018138049A5 (enExample) | ||
| JP2015096070A5 (enExample) | ||
| MX2020003176A (es) | Variantes de capsides de virus adenoasociados y metodos de uso de estas. | |
| JP2018506286A5 (enExample) | ||
| JP2016052331A5 (enExample) | ||
| JP2018510622A5 (enExample) | ||
| EA201890220A1 (ru) | Вакцина против rsv | |
| JP2017514522A5 (enExample) | ||
| JP2014530003A5 (enExample) | ||
| JP2019214579A5 (enExample) | ||
| FI3581650T3 (fi) | IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi | |
| RU2015135890A (ru) | Композиция вакцины | |
| JP2013543499A5 (enExample) | ||
| JP2018531624A5 (enExample) | ||
| JP2014224126A5 (enExample) | ||
| JP2015212284A5 (enExample) | ||
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
| JP2016501266A5 (enExample) |